Since KRAS activation stimulates signalling through both the PI3K and MEK pathways, there have been several studies investigating the efficacy of co-targeting the PI3K and MEK pathways in NSCLC [18]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.